SCHEMBL3037026

SCHEMBL3037026

O=C(NO)c1cccc(-c2cccc(C(=O)NC3CCCCC3)c2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.65
RAB9A P51151 4/20 0.65
NPC1 O15118 3/20 0.65
L3MBTL1 Q9Y468 1/20 0.62
SMN1; SMN2 Q16637 2/20 0.60
HSD17B10 Q99714 2/20 0.60
KDM4E B2RXH2 1/20 0.60
GFER P55789 1/20 0.60
HDAC8 Q9BY41 1/20 0.59
PKM P14618 1/20 0.57
HPGD P15428 1/20 0.56
HTR2B P41595 1/20 0.56
KDM1A O60341 1/20 0.56
ALDH1A1 P00352 1/20 0.55
HTT P42858 1/20 0.54
LMNA P02545 1/20 0.54
FAAH O00519 1/20 0.53
TRPA1 O75762 1/20 0.53
EPHX2 P34913 1/20 0.53
FAAH2 Q6GMR7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1928387 0.90 RAB9A (0.67) ERN1RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL2980074 0.88 PKM (0.68) ERN1RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL9265040 0.86 RAB9A (0.79) RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10
SCHEMBL6707186 0.86 RAB9A (0.79) RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10
SCHEMBL6569847 0.82 NPC1 (0.72) RAB9ANPC1SMN1; SMN2KDM4EHDAC8
SCHEMBL3031654 0.82 NPC1 (0.58) RAB9ANPC1L3MBTL1SMN1; SMN2HDAC8
SCHEMBL613993 0.82 RAB9A (0.68) RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10
SCHEMBL17552158 0.82 RAB9A (0.68) ERN1RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL3023480 0.81 NPC1 (0.66) RAB9ANPC1SMN1; SMN2KDM4EHDAC8
SCHEMBL19445791 0.81 RAB9A (0.72) RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216796-A1 N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS KATTAR SOLOMON 2010-08-26 US claimed
US-20100216796-A1 N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS KATTAR SOLOMON 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216796-A1 N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS BRDT, AADAC, ACIN1 ERN1 3832/4885RAB9A 4531/4885NPC1 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.